ALK-Abello | pharmaphorum

Skip to main content

Thursday 9 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ALK-Abello

News

Man sneezing into his hand

First-in-class hay fever immunotherapy backed for NHS use

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

News

A nasal spray in the palm of a person's hand

First intranasal anaphylaxis drug launches in Germany

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first market, by ALK-Abello.

News

Dust mites on carpet

Dust mite allergy sufferers set for a new NHS treatment

ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.

Editor's Picks

US pharma tariffs of up to 100% finalised by Trump

Lilly bags FDA okay for Wegovy pill rival orforglipron

Eli Lilly makes $7.8bn takeover play for Centessa

Blackstone closes record $6.3bn life sciences fund

One in four diabetics has undiagnosed heart failure; study

Oncology

Interview at LSX 2026 with Roi Raz

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company